TG6050
Category: Press release
Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
current account advance
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
BT-001 ESMO 2024
Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
TG4050
Transgene’s Combined General Meeting of May 15, 2024
General meeting 2024
Transgene provides business and financial update for Q1 2024
Financial update Q1 2024
Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
Shareholders’ meeting 2024
Availability of Transgene’s 2023 Universal Registration Document
URD 2023
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
TG4050 AACR 2024
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
appointment Lucie Larguier et Christelle Schwoerer
